About Biofrontera Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biofrontera-us.com/
Frequently Asked Questions
What is the 52-week range for BFRI?
The 52-week high is $1.66 and the 52-week low is $0.555.
What is the P/E ratio for BFRI?
The P/E ratio data is currently unavailable.
What is the dividend yield for BFRI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 3.79%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -13.78%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.63.
Analyst Recommendation Trends
Wall Street analyst consensus for BFRI over the last few months:
Latest BFRI News
Transcript: Biofrontera Q2 2026 Earnings Conference Call
On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announce
Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults
With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a pre-cancerous skin
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose
FDA Approves Label Update For Biofrontera’s Ameluz Gel To Highlight Hypersensitivity Warnings
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208081s040lbl.pdf
Biofrontera (NASDAQ:BFRI) Passes Minervini Trend Template With High-Growth Momentum
BIOFRONTERA (BFRI) passes Mark Minervini's Trend Template with high-growth momentum, showing strong moving averages, relative strength, and accelerating EPS/sales growth.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-28 | Luebbert Hermann | -62,500 | - | - |
| 2026-07-28 | Luebbert Hermann | +62,500 | - | - |
| 2026-07-28 | Leffler Eugene Frederick | -31,250 | - | - |
| 2026-07-28 | Leffler Eugene Frederick | +31,250 | - | - |
| 2026-03-05 | Luebbert Hermann | -137,500 | - | - |
| 2026-03-05 | Luebbert Hermann | +137,500 | - | - |
| 2026-03-05 | Leffler Eugene Frederick | -87,500 | - | - |
| 2026-03-05 | Leffler Eugene Frederick | +87,500 | - | - |
| 2026-03-04 | Weber Kevin Daniel | +20,000 | - | - |
| 2026-03-04 | Luebbert Hermann | +125,000 | - | - |
| 2026-03-04 | Luebbert Hermann | +125,000 | - | - |
| 2026-03-04 | Leffler Eugene Frederick | +62,500 | - | - |
| 2026-03-04 | Leffler Eugene Frederick | +62,500 | - | - |
| 2026-03-04 | Lanckriet Heikki | +20,000 | - | - |
| 2026-03-04 | Hoffman Beth J. | +20,000 | - | - |
| 2026-03-04 | Jones George Patrick | +50,000 | - | - |
| 2026-03-04 | Jones George Patrick | +50,000 | - | - |
| 2026-03-04 | BORER JOHN J III | +20,000 | - | - |